Cannabinoid receptor CB 2 protects against balloon-induced neointima formation

American Journal of Physiology - Heart and Circulatory Physiology

Volumn 302, Issue 5, 2012, Pages

  Molica, Filippo ^a   Matter, Christian M ^b   Burger, Fabienne ^a   Pelli, Graziano ^a   Lenglet, Sébastien ^a   Zimmer, Andreas ^c   Pacher, Pal ^d   Steffens, Sabine ^a  

^a UNIVERSITY HOSPITAL   (Switzerland)

^b UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^c UNIVERSITY OF BONN   (Germany)

^d NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM   (United States)

Author keywords

Macrophages; Restenosis; Smooth muscle cells

Indexed keywords

1 DEOXY 3 (1,1 DIMETHYLBUTYL) DELTA8 TETRAHYDROCANNABINOL; APOLIPOPROTEIN E; CANNABINOID 2 RECEPTOR; CHEMOKINE RECEPTOR CCR1; COLLAGEN; FIBRONECTIN; MESSENGER RNA; MONOCYTE CHEMOTACTIC PROTEIN 1; PLASTIC; CNR2 PROTEIN, MOUSE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AORTA; APOPTOSIS; ARTICLE; BONE MARROW CELL; CAROTID ARTERY OBSTRUCTION; CELL ADHESION; CELL ISOLATION; CELL PROLIFERATION; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; GENE DELETION; GENE EXPRESSION; HISTOPATHOLOGY; HYPERCHOLESTEROLEMIA; KNOCKOUT MOUSE; MACROPHAGE; MACROPHAGE MIGRATION; MALE; MOUSE; NEOINTIMA; NICK END LABELING; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SMOOTH MUSCLE FIBER; TISSUE REPAIR; VASCULAR ENDOTHELIUM; WILD TYPE; ANIMAL; BIOSYNTHESIS; C57BL MOUSE; CAROTID ARTERY INJURY; CELL MOTION; CHOLESTEROL INTAKE; DRUG EFFECT; DRUG POTENTIATION; GENETICS; METABOLISM; MOUSE MUTANT; PATHOLOGY; PATHOPHYSIOLOGY; PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY; PHYSIOLOGY;

ANGIOPLASTY, BALLOON; ANIMALS; APOLIPOPROTEINS E; APOPTOSIS; CAROTID ARTERY INJURIES; CELL ADHESION; CELL MOVEMENT; CELL PROLIFERATION; CHOLESTEROL, DIETARY; MACROPHAGES; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MYOCYTES, SMOOTH MUSCLE; NEOINTIMA; RECEPTOR, CANNABINOID, CB2;

EID: 84857346670     PISSN: 03636135     EISSN: 15221539     Source Type: Journal    
DOI: 10.1152/ajpheart.00444.2011     Document Type: Article

References (41)

1. Arevalo-Martin A, Garcia-Ovejero D, Gomez O, Rubio-Araiz A, Navarro-Galve B, Guaza C, Molina-Holgado E, Molina-Holgado F. CB2 cannabinoid receptors as an emerging target for demyelinating diseases: from neuroimmune interactions to cell replacement strategies. Br J Pharmacol 153: 216-225, 2008.
2. Baker D, Pryce G, Croxford JL, Brown P, Pertwee RG, Huffman JW, Layward L. Cannabinoids control spasticity and tremor in a multiple sclerosis model. Nature 404: 84-87, 2000.
3. Batkai S, Osei-Hyiaman D, Pan H, El-Assal O, Rajesh M, Mukhopadhyay P, Hong F, Harvey-White J, Jafri A, Hasko G, Huffman JW, Gao B, Kunos G, Pacher P. Cannabinoid-2 receptor mediates protection against hepatic ischemia/reperfusion injury. FASEB J 21: 1788-1800, 2007.
4. Batkai S, Rajesh M, Mukhopadhyay P, Hasko G, Liaudet L, Cravatt BF, Csiszar A, Ungvari Z, Pacher P. Decreased age-related cardiac dysfunction, myocardial nitrative stress, inflammatory gene expression, and apoptosis in mice lacking fatty acid amide hydrolase. Am J Physiol Heart Circ Physiol 293: H909-H918, 2007.
5. Bittl JA. Advances in coronary angioplasty. N Engl J Med 335: 1290-1302, 1996.
6. Daemen J, Wenaweser P, Tsuchida K, Abrecht L, Vaina S, Morger C, Kukreja N, Juni P, Sianos G, Hellige G, van Domburg RT, Hess OM, Boersma E, Meier B, Windecker S, Serruys PW. Early and late coronary stent thrombosis of sirolimus-eluting and paclitaxel-eluting stents in routine clinical practice: data from a large two-institutional cohort study. Lancet 369: 667-678, 2007.
7. Defer N, Wan J, Souktani R, Escoubet B, Perier M, Caramelle P, Manin S, Deveaux V, Bourin MC, Zimmer A, Lotersztajn S, Pecker F, Pavoine C. The cannabinoid receptor type 2 promotes cardiac myocyte and fibroblast survival and protects against ischemia/reperfusion-induced cardiomyopathy. FASEB J 23: 2120-2130, 2009.
8. Di Marzo V. The endocannabinoid system: its general strategy of action, tools for its pharmacological manipulation and potential therapeutic exploitation. Pharmacol Res 60: 77-84, 2009.
9. Di Marzo V, Bifulco M, De Petrocellis L. The endocannabinoid system and its therapeutic exploitation. Nat Rev Drug Discov 3: 771-784, 2004.
10. Douglas JS Jr. Pharmacologic approaches to restenosis prevention. Am J Cardiol 100: 10K-16K, 2007.
11. Ferns GA, Avades TY. The mechanisms of coronary restenosis: insights from experimental models. Int J Exp Pathol 81: 63-88, 2000.
12. Finn AV, Nakazawa G, Joner M, Kolodgie FD, Mont EK, Gold HK, Virmani R. Vascular responses to drug eluting stents: importance of delayed healing. Arterioscler Thromb Vasc Biol 27: 1500-1510, 2007.
13. Galkina E, Kadl A, Sanders J, Varughese D, Sarembock IJ, Ley K. Lymphocyte recruitment into the aortic wall before and during development of atherosclerosis is partially L-selectin dependent. J Exp Med 203: 1273-1282, 2006.
14. Guindon J, Hohmann AG. Cannabinoid CB2 receptors: a therapeutic target for the treatment of inflammatory and neuropathic pain. Br J Pharmacol 153: 319-334, 2008.
15. Hoyer FF, Steinmetz M, Zimmer S, Becker A, Lutjohann D, Buchalla R, Zimmer A, Nickenig G. Atheroprotection via cannabinoid receptor-2 is mediated by circulating and vascular cells in vivo. J Mol Cell Cardiol 51: 1007-1014, 2011.
16. Huffman JW, Liddle J, Yu S, Aung MM, Abood ME, Wiley JL, Martin BR. 3-(1=,1=-Dimethylbutyl)-1-deoxy-delta8-THC and related compounds: synthesis of selective ligands for the CB2 receptor. Bioorg Med Chem 7: 2905-2914, 1999.
17. Klein TW. Cannabinoid-based drugs as anti-inflammatory therapeutics. Nat Rev Immunol 5: 400-411, 2005.
18. Klein TW, Newton C, Larsen K, Lu L, Perkins I, Nong L, Friedman H. The cannabinoid system and immune modulation. J Leukoc Biol 74: 486-496, 2003.
19. Lotersztajn S, Teixeira-Clerc F, Julien B, Deveaux V, Ichigotani Y, Manin S, Tran-Van-Nhieu J, Karsak M, Zimmer A, Mallat A CB2 receptors as new therapeutic targets for liver diseases. Br J Pharmacol 153: 286-289, 2008.
20. Matter CM, Chadjichristos CE, Meier P, von Lukowicz T, Lohmann C, Schuler PK, Zhang D, Odermatt B, Hofmann E, Brunner T, Kwak BR, Luscher TF. Role of endogenous Fas (CD95/Apo-1) ligand in balloon-induced apoptosis, inflammation, and neointima formation. Circulation 113: 1879-1887, 2006.
21. Matter CM, Ma L, von Lukowicz T, Meier P, Lohmann C, Zhang D, Kilic U, Hofmann E, Ha SW, Hersberger M, Hermann DM, Luscher TF. Increased balloon-induced inflammation, proliferation, and neointima formation in apolipoprotein E (ApoE) knockout mice. Stroke 37: 2625-2632, 2006.
22. Miller AM, Stella N. CB(2) receptor-mediated migration of immune cells: it can go either way. Br J Pharmacol 153: 299-308, 2008.
23. Montecucco F, Burger F, Mach F, Steffens S. CB2 cannabinoid receptor agonist JWH-015 modulates human monocyte migration through defined intracellular signaling pathways. Am J Physiol Heart Circ Physiol 294: H1145-H1155, 2008.
24. Montecucco F, Lenglet S, Braunersreuther V, Burger F, Pelli G, Bertolotto M, Mach F, Steffens S. CB(2) cannabinoid receptor activation is cardioprotective in a mouse model of ischemia/reperfusion. J Mol Cell Cardiol 46: 612-620, 2009.
25. Mukhopadhyay P, Rajesh M, Pan H, Patel V, Mukhopadhyay B, Batkai S, Gao B, Hasko G, Pacher P. Cannabinoid-2 receptor limits inflammation, oxidative/nitrosative stress, and cell death in nephropathy. Free Radic Biol Med 48: 457-467, 2010.
26. Netherland CD, Pickle TG, Bales A, Thewke DP. Cannabinoid receptor type 2 (CB2) deficiency alters atherosclerotic lesion formation in hyperlipidemic Ldlr-null mice. Atherosclerosis 213: 102-108, 2010.
27. Pacher P, Steffens S. The emerging role of the endocannabinoid system in cardiovascular disease. Semin Immunopathol 31: 63-77, 2009.
28. Pertwee RG. Cannabinoids and multiple sclerosis. Mol Neurobiol 36: 45-59, 2007.
29. 2- receptor stimulation attenuates TNF-α-induced human endothelial cell activation, transendothelial migration of monocytes, and monocyte-endothelial adhesion. Am J Physiol Heart Circ Physiol 293: H2210-H2218, 2007.
30. Rajesh M, Mukhopadhyay P, Hasko G, Huffman JW, Mackie K, Pacher P. CB(2) cannabinoid receptor agonists attenuate TNF-alphainduced human vascular smooth muscle cell proliferation and migration. Br J Pharmacol 153: 347-357, 2008.
31. Rajesh M, Pan H, Mukhopadhyay P, Batkai S, Osei-Hyiaman D, Hasko G, Liaudet L, Gao B, Pacher P. Cannabinoid-2 receptor agonist HU-308 protects against hepatic ischemia/reperfusion injury by attenuating oxidative stress, inflammatory response, and apoptosis. J Leukoc Biol 82: 1382-1389, 2007.
32. Ray JL, Leach R, Herbert JM, Benson M. Isolation of vascular smooth muscle cells from a single murine aorta. Methods Cell Sci 23: 185-188, 2001.
33. Schober A. Chemokines in vascular dysfunction and remodeling. Arterioscler Thromb Vasc Biol 28: 1950-1959, 2008.
34. Steffel J, Eberli FR, Luscher TF, Tanner FC. Drug-eluting stents-what should be improved? Ann Med 40: 242-252, 2008.
35. Steffens S, Veillard NR, Arnaud C, Pelli G, Burger F, Staub C, Karsak M, Zimmer A, Frossard JL, Mach F. Low dose oral cannabinoid therapy reduces progression of atherosclerosis in mice. Nature 434: 782-786, 2005.
36. Windecker S, Meier B. Late coronary stent thrombosis. Circulation 116: 1952-1965, 2007.
37. Wright KL, Duncan M, Sharkey KA. Cannabinoid CB2 receptors in the gastrointestinal tract: a regulatory system in states of inflammation. Br J Pharmacol 153: 263-270, 2008.
38. Xu H, Cheng CL, Chen M, Manivannan A, Cabay L, Pertwee RG, Coutts A, Forrester JV. Anti-inflammatory property of the cannabinoid receptor-2-selective agonist JWH-133 in a rodent model of autoimmune uveoretinitis. J Leukoc Biol 82: 532-541, 2007.
39. Zhang M, Martin BR, Adler MW, Razdan RK, Jallo JI, Tuma RF. Cannabinoid CB(2) receptor activation decreases cerebral infarction in a mouse focal ischemia/reperfusion model. J Cereb Blood Flow Metab 7: 1387-1396, 2007.
40. Zhao Y, Liu Y, Zhang W, Xue J, Wu YZ, Xu W, Liang X, Chen T, Kishimoto C, Yuan Z. WIN55212-2 ameliorates atherosclerosis associated with suppression of pro-inflammatory responses in ApoE-knockout mice. Eur J Pharmacol 649: 285-292, 2010.
41. Zhao Y, Yuan Z, Liu Y, Xue J, Tian Y, Liu W, Zhang W, Shen Y, Xu W, Liang X, Chen T. Activation of cannabinoid CB2 receptor ameliorates atherosclerosis associated with suppression of adhesion molecules. J Cardiovasc Pharmacol 55: 292-298, 2010.